Previous 10 | Next 10 |
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related diso...
In alphabetical order, what do Alcanna (TSX: CLIQ) , BELLUS Health (TSX:BLU) (NASDAQ:BLU) , Cineplex (TSX:CGX) , and Diversified Royalty (TSX:DIV) have in common? Well, these four stocks are the top buys on the TSX in May 2021. If you have $2,000 ...
Bellus Health (TSX:BLU) (NASDAQ:BLU) is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hyper-sensitization disorders. The company is developing BLU-5937 for the treatment of chronic cough. Hyper-sensi...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today a...
BELLUS Health (BLU): Q1 GAAP EPS of -$0.20 misses by $0.06.Revenue of $4K (flat Y/Y).Press Release For further details see: BELLUS Health EPS misses by $0.06
- Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 - - Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until en...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related diso...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appoin...
NEW YORK, March 19, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against BELLUS Health Inc. (“BELLUS”) (NASDAQ: BLU) in the United States District Court for the Southern District of New York on behalf of those who ...
News, Short Squeeze, Breakout and More Instantly...
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Canada NewsWire LONDON , June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed ...
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced the positive outcome of the BELLUS shareholders (“ Shareholders ”) vote at this morning’s special meeting of the Shareholders (the “ ...
Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding o...